New safety strategy tested for rare bleeding disorder
NCT ID NCT04563520
Summary
This study aims to find a safer, personalized low dose of a clotting medication called FEIBA for children and adults with severe hemophilia A who are already taking emicizumab. Researchers want to see if this approach can effectively control bleeding while minimizing risks like blood clots. The goal is to gather data to help manage future bleeding episodes and surgeries more safely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.